Dashboard
Manage Tickers

NRSNNeuroSense Therapeutics Ltd.

Nasdaq neurosense-tx.com


$ 0.69 $ 0.00 (0 %)    

Wednesday, 14-Aug-2024 12:44:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.74 $ 0.15 (0.03 %)
DIA $ 400.12 $ 2.30 (0.58 %)
SPY $ 543.85 $ 1.71 (0.32 %)
TLT $ 97.88 $ 0.61 (0.63 %)
GLD $ 226.19 $ -1.86 (-0.82 %)
$ 0.7
$ 0.60 x 200
-- x --
-- - --
$ 0.40 - $ 2.33
39,595
na
10.77M
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

neurosense-therapeutics-announces-600k-private-placement-agreement-to-sell-800k-ordinary-shares-and-800k-warrants-at-075-per-share-10-above-august-6-closing-price
NeuroSense Therapeutics Announces $600K Pr...
08/07/2024 18:00:57

neurosense-therapeutics-announces-biomarker-data-from-als-phase-2b-clinical-trial-met-its-safety-and-efficacy-endpoints-including-reducing-functional-and-respiratory-deterioration-and-statistically-significant-changes-in-als-related-biological-markers-indicating-primecs-biological-activity
NeuroSense Therapeutics Announces Biomarke...
08/01/2024 13:22:09

12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigationPrevious re...

neurosense-highlights-paradigm-clinical-trial-data-co-to-submit-12-month-data-to-fda-to-discuss-path-forward
NeuroSense Highlights PARADIGM Clinical Tr...
07/09/2024 13:29:47

In the study, complication-free survival revealed a 57% difference in favor of PrimeC over placebo after 12 months of treatment...

neurosense-shares-are-trading-higher-after-the-company-reported-results-from-a-12-month-analysis-of-its-paradigm-phase-2b-study-evaluating-primec-in-als-patients-showing-that-disease-progression-was-slowed-by-36-compared-to-the-placebo
NeuroSense shares are trading higher after...
07/01/2024 12:04:33

neurosense-reports-results-from-12-month-analysis-of-its-paradigm-phase-2b-study-evaluating-primec-in-als-patients-disease-progression-was-slowed-by-36-v-placebo
NeuroSense Reports Results From 12-Month A...
07/01/2024 12:03:55

neurosense-therapeutics-receives-notice-of-allowance-for-us-patent-application-on-ciprofloxacin--celecoxib-compositions-for-treating-als-and-alzheimers-disease
NeuroSense Therapeutics Receives Notice Of...
06/28/2024 14:20:34

https://patentcenter.uspto.gov/applications/18047289/ifw/docs

neurosense-therapeutics-q1-eps-035-misses-020-estimate
NeuroSense Therapeutics Q1 EPS $(0.35) Mis...
06/24/2024 13:02:14

NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimat...

neurosense-receives-nasdaq-delisting-notice
NeuroSense Receives Nasdaq Delisting Notice
06/21/2024 20:34:42

neurosense-therapeutics-partners-with-phasev-for-clinical-trial-analysis-and-optimization-in-respect-to-also-phase-3-trial-using-advanced-causal-machine-learning
NeuroSense Therapeutics Partners With Phas...
05/14/2024 13:05:46

-SEC

neurosense-announces-new-data-analysis-from-paradigm-clinical-trial-demonstrating-statistically-significant-slowing-of-disease-progression-in-high-risk-als-patients-primec-slowed-disease-progression-by-43-in-pre-specified-high-risk-als-patients
NeuroSense Announces New Data Analysis Fro...
05/07/2024 12:54:19

PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patientsConsistent data across subgroups under...

neurosense-shares-are-trading-higher-after-the-company-announced-an-alzheimers-drug-development-collaboration-with-genetika
NeuroSense shares are trading higher after...
04/22/2024 12:33:02

neurosense-and-genetika-initiate-precision-medicine-collaboration-beginning-with-ongoing-phase-2-clinical-trial-in-alzheimers-disease
NeuroSense and Genetika+ Initiate Precisio...
04/22/2024 12:31:27

neurosense-presents-data-validating-phase-2b-topline-readout-during-emerging-science-presentation-at-american-academy-of-neurology-annual-meeting
NeuroSense Presents Data Validating Phase ...
04/18/2024 12:34:24

Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consiste...

neurosense-to-present-paradigm-data-at-american-academy-of-neurology-annual-meeting
NeuroSense To Present PARADIGM Data At Ame...
04/12/2024 12:36:00

reported-earlier-neurosense-therapeutics-prices-45m-registered-direct-offering-of-298m-shares-and-concurrent-private-placement
Reported Earlier, NeuroSense Therapeutics ...
04/11/2024 06:23:56

NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it ha...

neurosense-collaborates-with-lonza-to-identify-exosome-based-biomarkers-for-advance-neurodegenerative-disease-treatments-and-diagnostics
NeuroSense Collaborates With Lonza To Iden...
04/09/2024 12:51:25

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neur...

neurosense-therapeutics-q4-eps-016-beats-023-estimate
NeuroSense Therapeutics Q4 EPS $(0.16) Bea...
04/05/2024 20:49:13

NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate ...

neurosense-fy23-eps-083-beats-085-estimate
NeuroSense FY23 EPS $(0.83) Beats $(0.85) ...
04/05/2024 13:30:43

neurosense-reports-results-from-its-als-phase-2b-paradigm-trial
NeuroSense Reports Results From Its ALS Ph...
02/21/2024 13:32:21

PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALSSt...

neurosense-regains-nasdaq-compliance
NeuroSense Regains Nasdaq Compliance
02/07/2024 14:28:31

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION